YBX1 and neoplasm: This fact makes Ad-Delo3-RGD treatment of patients with recurrent GBM, who achieved chemo-radiotherapy, an interesting virotherapeutic strategy, since notably these patients will present high amounts of activated YB-1 in their tumor cells.